LY-3041658 is a Monoclonal Antibody owned by Eli Lilly and Co, and is involved in 4 clinical trials, which were completed.

LY-3041658 exhibits therapeutic intervention by inhibiting both CXCR1 and CXCR2 ligands. These chemokine ligands play an important role in immunological responses including the migration of neutrophils to sites of inflammation and angiogenesis.

The revenue for LY-3041658 is expected to reach a total of $331m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the LY-3041658 NPV Report.

LY-3041658 is originated and owned by Eli Lilly and Co.

LY-3041658 Overview

LY-3041658 is under development for the treatment of psoriasis and hidradenitis suppurativa. It is a monoclonal antibody which is administered through subcutaneous and intravenous routes. The drug candidate is a new biological entity, that acts by targeting CXCR1 and CXCR2 ligands.

Eli Lilly and Co Overview

Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

The company reported revenues of (US Dollars) US$28,318.4 million for the fiscal year ended December 2021 (FY2021), an increase of 15.4% over FY2020. In FY2021, the company’s operating margin was 21%, compared to an operating margin of 24.7% in FY2020. In FY2021, the company recorded a net margin of 19.7%, compared to a net margin of 25.2% in FY2020. The company reported revenues of US$6,941.6 million for the third quarter ended September 2022, an increase of 7% over the previous quarter.

Quick View – LY-3041658

Report Segments
  • Innovator
Drug Name
  • LY-3041658
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Immunology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.